Abstract
This chapter will review available evidence for management of patients with chronic kidney disease and end-stage renal disease who are undergoing anticancer therapy. Both conventional chemotherapy and targeted biological therapies will be reviewed with respect to safety and necessary dose adjustments, to account for the reduced kidney function in this population of patients.
| Original language | English (US) |
|---|---|
| Title of host publication | Onco-Nephrology |
| Publisher | Elsevier |
| Pages | 183-196.e7 |
| ISBN (Electronic) | 9780323549455 |
| ISBN (Print) | 9780323549615 |
| DOIs | |
| State | Published - Jan 1 2019 |
Bibliographical note
Publisher Copyright:© 2020 Elsevier Inc. All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Chemotherapy
- Chronic kidney disease
- Dose adjustment
- End-stage renal disease
- Pharmacokinetics
- Targeted therapy
Fingerprint
Dive into the research topics of 'Chemotherapy in chronic kidney disease and dialysis'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS